Clinical Trials Browser

Has announcements × Leukemia, Lymphocytic, Chronic, B-Cell × duvelisib × Clear all

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Phase 3 Completed

319 enrolled 18 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell